Evidence map›Paper›PMID 41252107›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026

The cost-effectiveness of enzyme replacement therapies versus best supportive care for treating late onset Pompe disease in the UK NHS.

Matthew Walton, Nyanar Jasmine Deng, Mark Corbett, Chinyereugo Umemneku-Chikere, Sarah Nevitt, Helen Fulbright, Chong Yew Tan, Robin Lachmann, Rachel Churchill, Robert Hodgson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matthew WaltonCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.
Nyanar Jasmine DengCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.
Mark CorbettCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.
Chinyereugo Umemneku-ChikereCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.
Sarah NevittCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.
Helen FulbrightCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.
Chong Yew TanDepartment of Metabolic Medicine, Cambridge University Hospitals NHS Foundation Trust 7, Cambridge, UK.
Robin LachmannUniversity College London Hospitals NHS Foundation Trust, National Hospital for Neurology and Neurosurgery, London, UK.
Rachel ChurchillCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.
Robert HodgsonCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK. rob.hodgson@york.ac.uk.ORCID http://orcid.org/0000-0001-6962-2893

Funding

Evidence Synthesis Programme NIHR16121
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cost–benefit analysisEnzyme replacement therapyGlycogen storage disease type IIUnited Kingdom

Identifiers

PMID41252107
PMCPMC13451420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.